Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PDSB | 8-K | bearish | 6/10 | PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 100% of net proceeds | Sep 4, 2026 |
| GRML | 8-K | bearish | 7/10 | Greenland Mines Ltd completed its acquisition of the Sarfartoq mineral project in Greenland via merger with NNSR Holding | Sep 4, 2026 |
| PULM | S-4/A | bearish | 7/10 | Pulmatrix filed Amendment No. 2 to its S-4 registration statement, advancing the proposed reverse merger with Eos SENOLY | Sep 4, 2026 |
| RPRX | PRESS-RELEASE | bearish | 5/10 | Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in athe | Sep 4, 2026 |
| RGPX | 8-K | bearish | 7/10 | Regenerex Pharma's auditor, dbbmckennon, resigned effective August 31, 2026, after serving since 2017. The resignation i | Sep 4, 2026 |
| ISPC | 8-K | neutral | 6/10 | iSpecimen Inc. entered into an Asset Purchase Agreement to acquire AI software assets (Disease-Associated Protein Discov | Sep 4, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $1.5M from its existing $50M revolving credit facility with Parkview Holdings One | Sep 4, 2026 |
| MTNB | 8-K | bearish | 7/10 | Matinas BioPharma received a third NYSE American non-compliance notice, this time for failing Section 1003(a)(i) requiri | Sep 4, 2026 |
| NVO | COURT-RULING | neutral | 1/10 | A magistrate judge in the Novo Nordisk patent lawsuit against Mochi Health Corp. issued a procedural order governing in- | Sep 4, 2026 |
| IONS | 8-K | bearish | 7/10 | Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of pelacarsen did not | Sep 4, 2026 |
| ESPR | COURT-RULING | bullish | 5/10 | Esperion Therapeutics won a favorable claim construction ruling in the Nexletol/Nexlizet ANDA litigation. The court adop | Sep 4, 2026 |
| DNLI | CLUSTER | neutral | 2/10 | Two Denali Therapeutics insiders (COFO/Secretary Schuth and Director Thornberry) sold a combined $312K in open-market tr | Sep 4, 2026 |
| CATX | CLUSTER | neutral | 3/10 | Two 10% owner entities (Lantheus Holdings and Lantheus Alpha Therapy) sold a combined $491K of CATX shares over two days | Sep 4, 2026 |
| ALEC | CLUSTER | neutral | 3/10 | Three C-suite insiders at Alector (ALEC) sold a total of $285K in open-market sales over a 7-day window, including the C | Sep 4, 2026 |
| ARVN | 144 | neutral | 3/10 | Former officer Noah Berkowitz filed Form 144 notices to sell 8,300 shares of Arvinas common stock, valued at approximate | Sep 4, 2026 |
| VRAX | 6-K | bearish | 7/10 | Virax Biolabs filed a sticker prospectus supplement to increase the maximum aggregate offering amount under its existing | Sep 4, 2026 |
| AVXL | DEFA14A | neutral | 6/10 | Anavex Life Sciences filed a DEFA14A updating its proxy solicitation website (www.voteanavex.com) ahead of the September | Sep 4, 2026 |
| INDP | 424B5 | bearish | 6/10 | Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting a clerical error in | Sep 4, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | Three top executives at Maze Therapeutics (CEO, President R&D, CSBO) sold a combined ~$1.46M in shares over a three-day | Sep 4, 2026 |
| ELVN | 144 | neutral | 3/10 | Former board member Richard A. Heyman filed a Form 144 notice of intent to sell 38,000 shares of Enliven Therapeutics (E | Sep 4, 2026 |
| AKAN | 6-K | neutral | 4/10 | Akanda Corp. subsidiary First Towers & Fiber Corp. announced its first cash lease payment from a new 200-km fiber networ | Sep 4, 2026 |
| PRFX | EFFECT | bearish | 7/10 | PRF Technologies' registration statement (File No. 333-296943) became effective on September 3, 2026, enabling selling s | Sep 4, 2026 |
| VRAX | EFFECT | neutral | 3/10 | Virax Biolabs Group Ltd filed an EFFECT notice with the SEC on September 3, 2026, indicating that a registration stateme | Sep 4, 2026 |
| ONCO | EFFECT | bearish | 8/10 | Onconetix's S-1 registration (File No. 333-298259) became effective on September 3, 2026, enabling the resale of up to 1 | Sep 4, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganersen) as the first and only disease-modifying treatmen | Sep 4, 2026 |
| SNTI | DEFA14A | mixed | 6/10 | Senti Biosciences filed a DEFA14A (8-K) reporting $2.0M in additional senior secured convertible notes issued to NSG Bio | Sep 4, 2026 |
| BKHA | S-4/A | bearish | 7/10 | Black Hawk Acquisition Corp filed Amendment No. 8 to its S-4 registration statement for the proposed business combinatio | Sep 4, 2026 |
| XRTX | 6-K | bearish | 6/10 | XORTX Therapeutics re-engages IR Agency LLC for a $2.5M marketing and advertising campaign over three months, funded fro | Sep 4, 2026 |
| QNCX | 8-K | bearish | 8/10 | Quince Therapeutics received a Nasdaq delisting notice on August 31, 2026, for failing the minimum stockholders' equity | Sep 4, 2026 |
| VRXA | 6-K | neutral | 3/10 | Veraxa Biotech AG appointed Raju Willener as CFO effective September 4, 2026. Mr. Willener brings over 30 years of capit | Sep 4, 2026 |